Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)
A close-up of test tubes and laboratory equipment, showing the complexity of biopharmaceutical research.
The updated data showed that the treatment is well-tolerated and demonstrated durable responses with a confirmed ORR of 56%. Cedrik Britten, M.D., Chief Medical Officer at Immatics N.V. (NASDAQ:IMTX), stated the following on the development:
'Patients with advanced melanoma post-failure of checkpoint inhibition are left to face frequent and often rapid disease progression and limited long-term survival. These individuals are in urgent need of new treatments that deliver deeper and more durable responses. We believe the data presented today emphasize the strength, durability and tangible therapeutic potential of our one-time infusion PRAME cell therapy, IMA203, in this patient population. These positive results reinforce our commitment to actively advance IMA203 through the ongoing Phase 3 SUPRAME trial to bring this PRAME therapy to the market as soon as possible.'
Immatics N.V. (NASDAQ:IMTX) focuses on the research and development of potential T cell redirecting immunotherapies for cancer treatment. While the stock is down nearly 20% year-to-date, Wall Street analysts have a one-year average price target of $14.33 per share, reflecting a 151% upside potential from its current trading level.
On May 28, Deutsche Bank initiated coverage of Immatics N.V. (NASDAQ:IMTX) with a Buy rating and announced a price target of $10, with the firm's analysis suggesting a promising outlook for the company considering its approach to treating 2L+ Cutaneous Melanoma, especially with the IMA203.
While we acknowledge the potential of IMTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy and 13 Best Big Name Stocks to Buy Now.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
New Tariffs Threaten American Battery Production
Trump-era clean energy policies are slamming the breaks on the United States' battery war with China. While lithium-ion batteries were invented in the United States, China has been outpacing the nation in terms of both battery manufacturing and technological innovations. But while U.S. companies have been scrambling to keep up, gutted clean energy incentives and tariffs on critical materials have made a U.S. victory all but impossible. The domestic battery industry had been gaining considerable ground under the Biden administration thanks to major incentives including the sweeping Inflation Reduction Act. Tax credits, in particular, 'helped close the price gap between U.S.-made batteries and those made in China, the world's main supplier of lithium-ion battery modules, cells, and materials,' according to Canary Media. Realizing that the Trump administration would bring a less encouraging policy environment for clean energy technologies, makers of lithium-ion batteries promised the federal government that they would collectively spend a cumulative $100 billion by 2030 to build up an independent and totally domestic grid battery industry. In exchange, they asked for continued political support. So far, that plea seems to be falling flat. Just this month, the Trump administration accused Chinese suppliers of dumping graphite into U.S. markets – meaning that they are selling graphite more cheaply abroad than in their own markets. As a result, the United States has imposed a formidable 93.5 percent tariff on Chinese graphite. This could have immediate and serious consequences for United States batterymakers, as almost all refined graphite in the world comes from China. In fact, this tariff alone could 'easily add $1,000 or more to the price of a battery' according to the New York Times. As a result, the nation's once-thriving 'battery belt' is faltering. 'Projects are being paused, cancelled, and closed at a rate 6 times more than during the same period in 2024,' reports 'The Big Green Machine,' a site affiliated with Wellesley College that tracks domestic clean energy investments. And this biggest projects are the ones suffering most. Politico reports that 'prospects dimmed for 34 projects that are worth more than $31 billion and were expected to create almost 28,000 jobs.' This includes projects that are either paused, canceled, delayed by at least six faced by a slash in funding, or scaled down. But the overall impact of recent political shifts are still unclear, and overall the domestic clean energy sector is still growing. Related: 'The policies Republicans have passed are so recent that they may not have worked their way through the economy,' reports Politico. 'In the last three months, Congress has passed and President Donald Trump has signed bills that removed key tax credits, taken the teeth out of fuel-economy rules and neutered California's ability to force automakers to sell EVs.' Taken together, all of these compounding policy measures create an uncertain policy and investment environment at minimum. More likely, it will cause an extreme contraction of the domestic battery sector at a time when Beijing was already pulling away. "Unquestionably, the Chinese are ahead in manufacturing technology," Bob Galyen, a retired executive who worked with both GM and the Chinese battery giant CATL, told NPR. He says that Chinese battery research and development is receiving major influxes of cash at a time when U.S. manufacturers are struggling for funding. "Clearly, the U.S. is lagging behind,' he finished. Ironically, these measures are hitting Republican districts the hardest. The so-called 'battery belt' is mostly comprised of red states. As a result, according to Politico, 'GOP districts saw 60 percent of the funding decline, while Democratic districts saw 39 percent.' By Haley Zaremba for More Top Reads From this article on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Why AppLovin (APP) Dipped More Than Broader Market Today
In the latest close session, AppLovin (APP) was down 2.95% at $379.17. This change lagged the S&P 500's daily loss of 1.6%. Elsewhere, the Dow saw a downswing of 1.23%, while the tech-heavy Nasdaq depreciated by 2.24%. Shares of the mobile app technology company have appreciated by 14.36% over the course of the past month, outperforming the Business Services sector's loss of 1.38%, and the S&P 500's gain of 2.25%. The investment community will be paying close attention to the earnings performance of AppLovin in its upcoming release. The company is slated to reveal its earnings on August 6, 2025. The company is expected to report EPS of $1.99, up 123.6% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $1.21 billion, showing a 12.34% escalation compared to the year-ago quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of $8.39 per share and revenue of $5.51 billion, which would represent changes of +85.21% and +17.02%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for AppLovin. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.03% increase. AppLovin is currently a Zacks Rank #3 (Hold). In the context of valuation, AppLovin is at present trading with a Forward P/E ratio of 46.54. This indicates a premium in contrast to its industry's Forward P/E of 21.61. We can additionally observe that APP currently boasts a PEG ratio of 2.33. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Technology Services industry had an average PEG ratio of 1.79. The Technology Services industry is part of the Business Services sector. This industry, currently bearing a Zacks Industry Rank of 97, finds itself in the top 40% echelons of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AppLovin Corporation (APP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Canopy Growth Corporation (CGC) Advances While Market Declines: Some Information for Investors
In the latest close session, Canopy Growth Corporation (CGC) was up +1.94% at $1.05. The stock outperformed the S&P 500, which registered a daily loss of 1.6%. Elsewhere, the Dow saw a downswing of 1.23%, while the tech-heavy Nasdaq depreciated by 2.24%. Coming into today, shares of the company had lost 19.53% in the past month. In that same time, the Medical sector lost 3.44%, while the S&P 500 gained 2.25%. Market participants will be closely following the financial results of Canopy Growth Corporation in its upcoming release. The company plans to announce its earnings on August 8, 2025. On that day, Canopy Growth Corporation is projected to report earnings of -$0.15 per share, which would represent year-over-year growth of 59.46%. Alongside, our most recent consensus estimate is anticipating revenue of $47.91 million, indicating a 0.99% downward movement from the same quarter last year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.46 per share and revenue of $198.45 million. These totals would mark changes of +84.56% and +2.66%, respectively, from last year. Investors might also notice recent changes to analyst estimates for Canopy Growth Corporation. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 5.38% lower. Canopy Growth Corporation currently has a Zacks Rank of #5 (Strong Sell). The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 183, which puts it in the bottom 26% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canopy Growth Corporation (CGC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
